Please try another search
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
| Name | Age | Since | Title |
|---|---|---|---|
| Jeremy Max Levin | 72 | 2020 | CEO & Chairperson |
| Tien Y. Wong | - | 2024 | Member of Medical Advisory Board |
| Lawrence B. Gozlan | 46 | 2020 | Independent Non-Executive Director |
| Katherine Ellen-Danielle Connell | 58 | 2024 | Independent Non-Executive Director |
| Patricio G. Schlottmann | - | 2024 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review